Wallace L. Akerley

Wallace L. Akerley

Auto-generated profile, based on publicly available information

Wallace L. Akerley

Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in JCO Oncology Practice
Verified
Journal Article
Closed access
KKKathleen Kerrigan
Kathleen Kerrigan
SPShiven B. Patel
Shiven B. Patel
BHBenjamin Haaland
Benjamin Haaland
DODominik Ose
Dominik Ose
ACAnna Weinberg Chalmers
Anna Weinberg Chalmers
WAWallace Akerley
Wallace Akerley
PURPOSE: Performance status (PS), an established prognostic surrogate of cancer survival, is a physician-synthesized metric of patient symptoms and mobility that is prone to bias and subjectivity. The National Cancer Institute (NCI) Patient-Reported Outcomes Measurement Information System–Cancer (PROMIS-Ca) Bank, a patient-centric patient-reported outcome (PRO) evaluation of physical function (PF), fatigue, depression, anxiety, and pain, shares subject matter with PS and, therefore, may also be prognostic while eliminating physician interpretation. METHODS: Patients at Huntsman Cancer Institute were assessed using the NCI PROMIS-Ca Bank. Using tablets at routine office visits, PF, fatigue, depression, anxiety, and pain scores were collected from patients with advanced melanoma, non–small-cell lung cancer, colorectal cancer, and breast cancer. A PRO score collected at a single time point within 6 months of metastatic diagnosis for each patient was merged with curated clinical outcome data. The association of PROs, overall survival (OS), and hospitalization-free survival (HFS) were assessed in multivariable analysis that included sex and cancer type. RESULTS: Two hundred eighty-two complete sets of patient data were available for analysis. All 5 PRO domains were strongly prognostic of OS and HFS. While the PRO domains were interrelated with moderate to strong correlations (0.40-0.79), multivariable regression suggested that PF was most strongly associated with the clinical outcomes of OS ( P < .001) and HFS ( P < .001). CONCLUSION: NCI PROMIS-Ca PROs may be prognostic of both cancer survival and likelihood of hospitalization. Future prospective studies are needed for all major prognostic factors to fully understand the independent prognostic value of PROs.

30 April 2003 in Cancer
Verified
Journal Article
Closed access
PDF file
WAWallace Akerley
Wallace Akerley
JHJames E. Herndon
James E. Herndon
MEMerrill J. Egorin
Merrill J. Egorin
ALAlan P. Lyss
Alan P. Lyss
HKHedy L. Kindler
Hedy L. Kindler
MGMark R. Green
Mark R. Green

31 January 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JOJudy Ou
Judy Ou
BFBrynn Fowler
Brynn Fowler
QDQian Ding
Qian Ding
AKAnne C Kirchhoff
Anne C Kirchhoff
LPLisa Pappas
Lisa Pappas
DKDeanna Kepka
Deanna Kepka
Lung cancer is the leading cause of cancer-related mortality in Utah despite having the nation’s lowest smoking rate. Radon exposure and differences in lung cancer incidence between nonmetropolitan and metropolitan areas may explain this phenomenon. We compared smoking-adjusted lung cancer incidence rates between nonmetropolitan and metropolitan counties by predicted indoor radon level, sex, and cancer stage. We also compared lung cancer incidence by county classification between Utah and all SEER sites. SEER*Stat provided annual age-adjusted rates per 100,000 from 1991 to 2010 for each Utah county and all other SEER sites. County classification, stage, and sex were obtained from SEER*Stat. Smoking was obtained from Environmental Public Health Tracking estimates by Ortega et al. EPA provided low (< 2 pCi/L), moderate (2–4 pCi/L), and high (> 4 pCi/L) indoor radon levels for each county. Poisson models calculated overall, cancer stage, and sex-specific rates and p-values for smoking-adjusted and unadjusted models. LOESS smoothed trend lines compared incidence rates between Utah and all SEER sites by county classification. All metropolitan counties had moderate radon levels; 12 (63%) of the 19 nonmetropolitan counties had moderate predicted radon levels and 7 (37%) had high predicted radon levels. Lung cancer incidence rates were higher in nonmetropolitan counties than metropolitan counties (34.8 vs 29.7 per 100,000, respectively). Incidence of distant stage cancers was significantly higher in nonmetropolitan counties after controlling for smoking (16.7 vs 15.4, p = 0.02*). Incidence rates in metropolitan, moderate radon and nonmetropolitan, moderate radon counties were similar. Nonmetropolitan, high radon counties had a significantly higher incidence of lung cancer compared to nonmetropolitan, moderate radon counties after adjustment for smoking (41.7 vs 29.2, p < 0.0001*). Lung cancer incidence patterns in Utah were opposite of metropolitan/nonmetropolitan trends in other SEER sites. Lung cancer incidence and distant stage incidence rates were consistently higher in nonmetropolitan Utah counties than metropolitan counties, suggesting that limited access to preventative screenings may play a role in this disparity. Smoking-adjusted incidence rates in nonmetropolitan, high radon counties were significantly higher than moderate radon counties, suggesting that radon was also major contributor to lung cancer in these regions. National studies should account for geographic and environmental factors when examining nonmetropolitan/metropolitan differences in lung cancer.

27 October 2021 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
PRPatricia Rich
Patricia Rich
RMR Brian Mitchell
R Brian Mitchell
ESEric Schaefer
Eric Schaefer
PWPaul R Walker
Paul R Walker
JDJohn W Dubay
John W Dubay
WAWallace Akerley
Wallace Akerley
Purpose Immune checkpoint inhibition (ICI) therapy has improved patient outcomes in advanced non-small cell lung cancer (NSCLC), but better biomarkers are needed. A clinically validated, blood-based proteomic test, or host immune classifier (HIC), was assessed for its ability to predict ICI therapy outcomes in this real-world, prospectively designed, observational study. Materials and methods The prospectively designed, observational registry study INSIGHT (Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects) (NCT03289780) includes 35 US sites having enrolled over 3570 NSCLC patients at any stage and line of therapy. After enrolment and prior to therapy initiation, all patients are tested and designated HIC-Hot (HIC-H) or HIC-Cold (HIC-C). A prespecified interim analysis was performed after 1-year follow-up with the first 2000 enrolled patients. We report the overall survival (OS) of patients with advanced stage (IIIB and IV) NSCLC treated in the first-line (ICI-containing therapies n=284; all first-line therapies n=877), by treatment type and in HIC-defined subgroups. Results OS for HIC-H patients was longer than OS for HIC-C patients across treatment regimens, including ICI. For patients treated with all ICI regimens, median OS was not reached (95% CI 15.4 to undefined months) for HIC-H (n=196) vs 5.0 months (95% CI 2.9 to 6.4) for HIC-C patients (n=88); HR=0.38 (95% CI 0.27 to 0.53), p<0.0001. For ICI monotherapy, OS was 16.8 vs 2.8 months (HR=0.36 (95% CI 0.22 to 0.58), p<0.0001) and for ICI with chemotherapy OS was unreached vs 6.4 months (HR=0.41 (95% CI 0.26 to 0.67), p=0.0003). HIC results were independent of programmed death ligand 1 (PD-L1). In a subgroup with PD-L1 ≥50% and performance status 0–1, HIC stratified survival significantly for ICI monotherapy but not ICI with chemotherapy. Conclusion Blood-based HIC proteomic testing provides clinically meaningful information for immunotherapy treatment decision in NSCLC independent of PD-L1. The data suggest that HIC-C patients should not be treated with ICI alone regardless of their PD-L1 expression.

1 March 2008 in Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
CAChristopher J. Anker
Christopher J. Anker
CDChristopher Dechet
Christopher Dechet
JIJorge C. Isaac
Jorge C. Isaac
WAWallace Akerley
Wallace Akerley
DSDennis C. Shrieve
Dennis C. Shrieve

1 March 2013 in Lung Cancer
Verified
Journal Article
Closed access
WAWallace Akerley
Wallace Akerley
KBKenneth Boucher
Kenneth Boucher
NRNathan Rich
Nathan Rich
LELyle Egbert
Lyle Egbert
GHGraydon Harker
Graydon Harker
CRChakravarthy Reddy
Chakravarthy Reddy